Trial Profile
A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Bronchial cancer; Duodenal cancer; Gastric cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 21 Feb 2023 Have added bronchial and lung cancer for bronchopulmonary (Bronchopulmonary neuroendocrine tumors (BP-NETs) comprise approximately 20% of all lung cancers )https://www.ncbi.nlm.nih.gov/pubmed/18473355.
- 10 Feb 2020 Status changed from active, no longer recruiting to completed.
- 20 Sep 2017 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.